Compare RVSB & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | RCEL |
|---|---|---|
| Founded | 1923 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 102.5M |
| IPO Year | 1993 | N/A |
| Metric | RVSB | RCEL |
|---|---|---|
| Price | $5.21 | $3.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $7.17 |
| AVG Volume (30 Days) | 48.8K | ★ 228.3K |
| Earning Date | 01-26-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 361.12 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | $52,756,000.00 | ★ $72,401,000.00 |
| Revenue This Year | $10.25 | $13.12 |
| Revenue Next Year | $11.23 | $27.56 |
| P/E Ratio | $23.64 | ★ N/A |
| Revenue Growth | 15.20 | ★ 20.59 |
| 52 Week Low | $4.74 | $3.22 |
| 52 Week High | $6.59 | $11.25 |
| Indicator | RVSB | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 66.13 |
| Support Level | $4.95 | $3.24 |
| Resistance Level | $5.13 | $3.57 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 90.14 | 95.83 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.